RAT BITE — CLINICIAN HANDOUT

                                                   

Patient: __________ DOB/Age: __________ MRN: __________ Date/Time: __________
Bite: ☐ Rat ☐ Other rodent: __________ Provoked? ☐ Yes ☐ No Domestic/pet vs wild: __________
Time since bite: __________ h/d Location: ☐ Hand ☐ Wrist/forearm ☐ Face ☐ Foot ☐ Other: __________
Comorbids (higher risk): ☐ Diabetes ☐ Immunosuppression ☐ Asplenia ☐ Cirrhosis ☐ Vascular insufficiency ☐ Other: __________
Allergies: __________ (reaction: __________)

1) Immediate assessment

• Vitals: T ___ HR ___ RR ___ BP ___ SpO₂ ___ Temp ___
• Red flags requiring urgent escalation/consult/admit:
  ☐ Uncontrolled bleeding ☐ Rapidly progressive swelling/pain ☐ Systemic toxicity ☐ Suspected deep-space hand infection
  ☐ Neurovascular compromise ☐ Suspected tendon/joint/bone involvement ☐ Necrosis/crepitus

2) Wound exam (document)

• Type: ☐ Puncture ☐ Laceration ☐ Crush ☐ Avulsion
• Depth/structures: ☐ Superficial ☐ Deep to fascia ☐ Tendon concern ☐ Joint capsule concern ☐ Bone exposed/seen
• Contamination/foreign body: ☐ None ☐ Dirt/debris ☐ Tooth/foreign body suspected
• Neurovascular/tendon function distal to wound: ☐ Intact ☐ Abnormal (details): __________

3) Wound care (do now)

• ☐ Copious irrigation (NS; high volume)
• ☐ Remove visible debris/foreign material; debride devitalized tissue as needed
• ☐ Analgesia (local/regional/systemic)
• ☐ Consider splint/elevation if hand/wrist involvement
• Primary closure? ☐ No (preferred for puncture/crush/hand/delayed/contaminated) ☐ Yes (criteria met; cosmetically/functional)
  If closed: method __________; follow-up arranged ☐ 24–48 h

4) Imaging / procedures / consult

• X-ray ☐ Yes ☐ No
  Indication: ☐ Foreign body ☐ Fracture ☐ Near joint ☐ Crush injury ☐ Other: __________
• Consult ☐ Hand/ortho ☐ Plastics ☐ ID ☐ Other: __________
  Reason: __________

5) Antibiotics (bite-wound prophylaxis vs treatment)

Use antibiotics for established infection (erythema, warmth, swelling, purulence, lymphangitis, fever) and consider prophylaxis for higher-risk wounds (e.g., hand, deep puncture/crush, devitalized tissue/contamination, suspected joint/bone/tendon involvement, poor circulation, immunocompromise). ⁽²⁾

• No skin break: ☐ No antibiotics
• Broken skin: prophylaxis indicated? ☐ Yes ☐ No
  Rationale (check): ☐ Hand/face/genitals ☐ Deep puncture/crush ☐ Delayed presentation ☐ Comorbidity risk ☐ Other: ______
• Signs of infection present? ☐ Yes ☐ No
• Regimen chosen:
  ☐ Amoxicillin–clavulanate __________ dose __________ route __________ duration __________
  ☐ Penicillin allergy alternative per local guideline: __________________ duration __________
  Notes: If a penicillin allergy is present and doxycycline-based regimens are being used, add anaerobic coverage as per local protocol where appropriate. ⁽³⁾

6) Rat-bite fever (RBF) screen (don’t miss)

RBF can present after rodent exposure with fever, rash, and arthralgia and may rarely lead to invasive disease (e.g., endocarditis); consider if systemic symptoms occur days–weeks after exposure.

• Symptoms now or since bite: ☐ Fever ☐ Rigors ☐ Rash (palms/soles/extremities) ☐ Migratory arthralgia/arthritis ☐ Vomiting/HA
• If suspected RBF:
  ☐ Blood cultures before antibiotics (if feasible)
  ☐ Evaluate for complications as indicated (cardiac exam ± echo if endocarditis concern)
  ☐ Treat as systemic infection per local/ID guidance (often IV beta-lactam or ceftriaxone; doxycycline is a common alternative in beta-lactam allergy)

7) Tetanus prophylaxis (always document)

• Wound category: ☐ Clean/minor ☐ Dirty/major (puncture, devitalized tissue, contaminated)
• Tetanus vaccine status:
  Last Td/Tdap: __________ Primary series complete? ☐ Yes ☐ No/Unknown
• Action:
  ☐ No vaccine needed
  ☐ Td/Tdap booster given today
  ☐ Tetanus immune globulin (TIG) given (if indicated)
  (Antibiotics are not used to prevent tetanus.) ⁽⁴⁾

8) Rabies risk documentation (usually low for rats)

• Animal available for assessment? ☐ Yes ☐ No
• Unusual circumstance (neurologic behavior / local outbreak / public health advice)? ☐ Yes ☐ No
• Plan: ☐ No rabies PEP indicated ☐ Public health consulted: __________ ☐ PEP started
  (If PEP is indicated: start with wound cleansing; HRIG + vaccine schedule per guidance.) ⁽¹⁾

9) Disposition & follow-up

• Disposition: ☐ Home ☐ Observation ☐ Admit (service: __________)
• Follow-up arranged: ☐ 24–48 h (hand/deep/closed/high risk) ☐ 3–5 d ☐ Other: __________
• Return precautions documented (clinician): worsening pain/swelling/erythema, purulence, fever, lymphangitis, reduced ROM, numbness/weakness, or systemic symptoms within 1–3 weeks (RBF concern).

If you tell me your local formulary preferences (or country/health system) and whether you want adult-only vs adult+peds, I can “lock” the antibiotic lines into exact doses/durations for your setting and keep it to a strict single page.

CITED SOURCES

1. Rabies Post-exposure Prophylaxis Guidance | Rabies | CDC. www.cdc.gov
2. Management of bites, human and animal - South & West.  southwest.devonformularyguidance.nhs.uk
3. Human and animal bites | Right Decisions.
   www.rightdecisions.scot.nhs.uk

   
   

Frequently Asked Questions: Molar Pregnancy (Hydatidiform Mole)

 

 

1. What is a molar pregnancy?

A molar pregnancy, or hydatidiform mole, is a rare complication of pregnancy where an abnormal fertilized egg develops into a mass of cysts instead of a healthy fetus. It is a type of gestational trophoblastic disease (GTD).

2. What causes a molar pregnancy?

It is caused by a genetic error during the fertilization process.

•         Complete mole: Occurs when one sperm fertilizes an "empty" egg (lacking maternal DNA). The genetic material is entirely paternal.

•         Partial mole: Occurs when two sperm fertilize one normal egg, resulting in too much genetic material (69 chromosomes instead of the usual 46).

3. What are the common symptoms?

Patients often present with symptoms similar to a normal pregnancy, but more intense:

•         Vaginal bleeding in the first trimester.

•         Severe nausea and vomiting (hyperemesis gravidarum).

•         Rapid uterine growth (uterus larger than expected for gestational age).

•         Passing grape-like cysts from the vagina.

•         High blood pressure, pre-eclampsia symptoms, or hyperthyroidism symptoms.

4. How is it diagnosed?

•         Ultrasound: Typically shows a "snowstorm" appearance or a cluster of grapes.

•         β-hCG levels: Blood tests show unusually high human chorionic gonadotropin (hCG) levels compared to a normal pregnancy of the same stage.

5. What is the treatment?

The standard treatment is an evacuation procedure, usually a Suction Dilatation and Curettage (D&C), to remove the abnormal tissue from the uterus. In some cases, if the patient has completed childbearing and the risk of complications is high, a hysterectomy might be discussed.

6. Why is follow-up so important?

Because there is a risk that some abnormal trophoblastic tissue remains or develops into a more serious, malignant form of GTD (such as choriocarcinoma), regular monitoring of β-hCG levels is mandatory. The goal is to ensure the level drops to zero and stays there.

7. What does the follow-up surveillance involve?

•         Weekly β-hCG: Until the level is undetectable for three consecutive weeks.

•         Monthly β-hCG: For six months following the first undetectable reading to ensure the mole does not recur.

8. Can I get pregnant again?

Yes, most women who have had a molar pregnancy go on to have healthy, normal pregnancies in the future. However, it is strongly advised to use effective contraception during the entire surveillance period. Becoming pregnant during this time would elevate hCG levels, making it impossible to tell if the mole has returned or is malignant.

9. Is a molar pregnancy a type of cancer?

Most molar pregnancies are benign and resolve completely after evacuation. However, in a small percentage of cases, the tissue can become invasive or malignant (Gestational Trophoblastic Neoplasia). This is why the follow-up monitoring is so critical—to detect and treat these cases early, usually with medication (chemotherapy).

10. Will I need chemotherapy?

Only if the β-hCG levels do not return to normal or if there is evidence of malignant trophoblastic disease. If needed, chemotherapy for GTD is highly effective and generally has a very high cure rate.

11. What are the psychological impacts of a molar pregnancy?

It is very common to experience a wide range of emotions, including shock, grief, sadness, and anxiety, even if the pregnancy was early. It is important to remember that a molar pregnancy is a medical event outside of your control. Reaching out for professional counseling, joining a support group, or speaking with your doctor about your feelings can be incredibly helpful during the recovery process.

12. Are there any increased risks for me in future pregnancies?

Generally, no. After a successful recovery and the surveillance period, you are not at a significantly higher risk of having another molar pregnancy. The risk of recurrence is very low (about 1–2%). Your healthcare provider will likely recommend early ultrasound in future pregnancies to confirm viability.

13. What is "Persistent Trophoblastic Disease" (PTD)?

PTD occurs when β-hCG levels do not decline as expected or begin to rise again during the surveillance period. This indicates that some abnormal tissue remains and continues to produce hCG. It is not necessarily "cancer" in the traditional sense, but it does require medical intervention, typically with specialized chemotherapy, to ensure the disease is fully cured.

14. Should I be concerned if my β-hCG levels plateau?

Yes. If β-hCG levels stop declining (plateau) or increase during the monitoring phase, your doctor will need to investigate. This is a common trigger for further imaging (like a chest X-ray or CT scan) to check for residual disease and will prompt a discussion about starting treatment to prevent further complications.

15. Are there different types of chemotherapy used for GTD?

Yes. The chemotherapy used for gestational trophoblastic disease (GTD) is often much more targeted and has different protocols than traditional cancer chemotherapy. Many patients only require a single drug, and the cure rate for this disease is remarkably high, often reaching near 100% with timely treatment.

GDM during the third trimester

 

LRTI: Discharge Criteria and Continued stay criteria

🏥 LRTI - Discharge Criteria & Continued Stay Criteria

Lower Respiratory Tract Infection Management Decision Points

✅ DISCHARGE CRITERIA - Click to Expand

✅ Criteria for Safe Hospital Discharge

Patients should meet ALL criteria before discharge is considered safe and appropriate.

Clinical Stability Criteria

📊 Vital Signs Normalization

• Temperature: ≤ 37.5°C (99.5°F) for ≥24 hours without antipyretics
• Heart Rate: 60-100 bpm (or baseline rate if known)
• Respiratory Rate: 12-20 breaths/minute
• Blood Pressure: Systolic ≥90 mmHg, Diastolic ≥60 mmHg (no vasopressors)
• SpO₂: ≥92% on room air (or baseline for COPD patients)
• Alert & Oriented: Normal mental status (no confusion/delirium)

🫁 Respiratory Function

• No Respiratory Distress: No tachypnea, stridor, or use of accessory muscles
• Adequate Oxygenation: pO₂ ≥60 mmHg on room air (or stable baseline)
• No Hypercapnia: pCO₂ normal range or chronic baseline
• Effective Cough: Able to expectorate secretions
• No Supplemental O₂ Requirement: Or minimal requirement (<2-3 L/min)

💊 Oral Intake & Medications

• Adequate Oral Intake: Able to eat and drink without difficulty
• No Dysphagia: No aspiration risk, normal swallowing
• Tolerating Oral Medications: No IV medications required
• Nausea/Vomiting Controlled: Not requiring IV antiemetics
• Bowel Function Intact: Regular bowel movements

Infectious Disease Criteria

🧬 Laboratory & Microbiological

• WBC Count: ≤11,000/μL (normalized or trending down)
• CRP/Procalcitonin: Normalized or significantly decreased
• Blood Cultures: Negative (if initially positive)
• Sputum Culture: No new pathogenic organisms identified
• No Fever: Afebrile for ≥24-48 hours
• Antibiotic Course: Completed appropriate duration (7-10 days for CAP)

📋 Discharge Readiness Checklist

☐

Vital Signs Stable - HR 60-100, RR 12-20, BP >90/60, SpO₂ >92%

☐

Afebrile - Temperature ≤37.5°C for ≥24 hours

☐

Adequate Oxygenation - SpO₂ ≥92% on room air

☐

Oral Intake Adequate - Eating/drinking well, no dysphagia

☐

Medication Tolerance - All antibiotics by mouth, no IV required

☐

Clinical Improvement - Cough, dyspnea improving

☐

Lab Normalization - WBC ≤11,000, CRP trending down

☐

Follow-up Arranged - Outpatient appointment within 1-2 weeks

⛔ CONTINUED STAY CRITERIA - Click to Expand

⛔ Criteria for Continued Hospitalization

Patients meeting ANY of these criteria should NOT be discharged.

Clinical Instability - RED FLAGS

🚨 Vital Sign Abnormalities

• Persistent Fever: Temperature >38°C despite antibiotics (>48-72 hours)
• Tachycardia: HR >120 bpm persistently
• Tachypnea: RR >24 breaths/minute or acute worsening
• Hypotension: SBP <90 mmHg requiring vasopressor support
• Hypoxemia: SpO₂ <90% on room air, requiring supplemental O₂
• Altered Mental Status: Confusion, delirium, decreased LOC

🫁 Respiratory Compromise

• Respiratory Distress: Use of accessory muscles, stridor, grunting
• Hypoxemia: pO₂ <60 mmHg despite supplemental oxygen
• Hypercapnia: pCO₂ >50 mmHg with respiratory acidosis
• Need for Mechanical Ventilation: Current intubation or impending need

Infectious Disease Criteria - RED FLAGS

🧬 Microbiological/Laboratory Concerns

• Positive Blood Cultures: Bacteremia present, requires investigation
• Persistent WBC Elevation: WBC >15,000/μL with left shift
• Rising CRP/Procalcitonin: Increasing inflammatory markers despite therapy
• Resistant Organisms: MRSA, MDR gram-negatives, fungal agents
• Treatment Failure: No improvement by 48-72 hours on antibiotics

⛔ Continued Stay RED FLAG Checklist

☐

Fever >48-72 hours - Temperature remains >38°C despite antibiotics

☐

Hypoxemia - SpO₂ <90% or pO₂ <60 mmHg

☐

Respiratory Distress - RR >24 or accessory muscle use

☐

Hemodynamic Instability - Hypotension, tachycardia, or shock

☐

Altered Mental Status - New confusion, delirium, decreased LOC

☐

Positive Blood Cultures - Evidence of bacteremia

☐

Resistant Organisms - MRSA, MDR gram-negatives, fungi

📋 CLINICAL ASSESSMENT TOOLS - Click to Expand

📋 Clinical Assessment Tools

CURB-65 Score at Discharge Assessment

CURB-65 Score	Discharge Readiness	Action
0-1 (Low Risk)	Excellent candidate for discharge	Discharge with outpatient follow-up; oral antibiotics
2 (Intermediate)	Safe to discharge if clinically stable	Monitor 24 hours; transition to oral meds
≥3 (High Risk)	Requires continued hospitalization	Do NOT discharge; continue IV antibiotics

PSI (Pneumonia Severity Index) - Risk Stratification

PSI Class	Mortality	Discharge Recommendation
Class I	<0.1%	✅ Safe outpatient management
Class II	0.6%	✅ Consider discharge after observation
Class III	0.9-1.3%	⚠️ Brief hospitalization required
Class IV	6.8-8.2%	❌ Hospitalization required
Class V	27-31%	❌ ICU-level care required

📞 FOLLOW-UP & DISCHARGE INSTRUCTIONS - Click to Expand

📞 Discharge & Follow-up Care Planning

Follow-up Schedule

Timeframe	Action/Assessment	By Whom
24-48 hours	Telephone check-in; confirm medication compliance	Nurse or PCP
1 week	In-person PCP visit; assess treatment response	Primary Care Physician
4 weeks	Assess symptom resolution; repeat labs if needed	Primary Care Physician
1-3 months	Repeat CXR if immunocompromised or prolonged symptoms	PCP or Pulmonology

⚠️ Warning Signs - Seek Emergency Care If:

• Return fever (>38.5°C)
• Worsening shortness of breath
• Chest pain or hemoptysis
• Mental status changes
• Severe fatigue or syncope

📚 These criteria are for clinical guidance and should be integrated with clinical judgment and institutional protocols.

References: IDSA, ATS Guidelines | Blogger-Compatible Version (CSS-only collapsible sections)

LRTI DIAGNOSIS

PRCS (Protected Respiratory Catheter Specimen) - Protected Specimen Brush:

• Bronchoscopic technique with direct visualization
• Protected catheter design prevents upper airway contamination
• Quantitative culture: ≥10³-10⁴ CFU/mL diagnostic for VAP
• Higher specificity (~90%) but more invasive
• Requires expertise and equipment

Extation (Endotracheal Aspiration):

• Simple blind bedside procedure with suction catheter
• No visualization needed
• Higher diagnostic threshold: ≥10⁴-10⁵ CFU/mL
• Higher sensitivity (~70-90%) but lower specificity (~60%)
• Cost-effective and readily available 24/7                                                                                    
•  

 

Acute Kidney Injury

 AKI Management Algorithm (Step-by-Step)

---

Step 1: Diagnose AKI

• Criteria:
• SCr increase ≥0.3 mg/dL within 48h or ≥1.5× baseline.
• Urine output <0.5 mL/kg/h for ≥6h.
• Rule out pseudorenal failure (e.g., dehydration, obstruction).

---

Step 2: Stage AKI (KDIGO)

Stage	SCr Criteria	Urine Output Criteria
1	≥0.3 mg/dL or 1.5–1.9× baseline	<0.5 mL/kg/h for 6–12h
2	2.0–2.9× baseline	<0.5 mL/kg/h for ≥12h
3	≥3.0× baseline or ≥4.0 mg/dL	<0.3 mL/kg/h for ≥24h or anuria

---

Step 3: Identify the Cause

Prerenal (60%)

• History/Exam: Hypotension, dehydration, heart failure.
• Labs: FeNa <1%, urine osmolality >500 mOsm/kg.
• Management: Fluid resuscitation, optimize hemodynamics.

Intrinsic (35%)

• ATN: Acute Tubular Necrosis: Ischemia, toxins (aminoglycosides, contrast).
• Labs: FeNa >2%, granular casts.
• Management: Discontinue nephrotoxins, supportive care.
• AIN: Acute interstitial nephritis:  Drugs (penicillin, PPIs, NSAIDs).
• Labs: Eosinophils in urine, rash, fever.
• Management: Stop offending drugs, ± steroids.
• Glomerulonephritis/Vasculitis:
• Labs: Proteinuria, hematuria, low C3/C4.
• Management: Immunosuppression (steroids, cyclophosphamide).

Postrenal (5%)

• History/Exam: Obstruction (stones, BPH, tumors).
• Imaging: Renal ultrasound (hydronephrosis).
• Management: Catheterization, nephrostomy, or stenting.

---

Step 4: Immediate Management

• For All AKI:
• Discontinue nephrotoxins (NSAIDs, ACEi/ARBs, aminoglycosides).
• Optimize hemodynamics (fluids, vasopressors if needed).
• Monitor:
• SCr, BUN, electrolytes (K⁺, Na⁺, Ca²⁺, PO₄³⁻).
• Urine output (Foley catheter if oliguric).
• Fluid balance (strict I/O).
• Correct Electrolyte Imbalances:
• Hyperkalemia (K⁺ >6.5 mEq/L):
• Calcium gluconate (10 mL IV over 10 min).
• Insulin + glucose (10 units insulin + 50 mL D50).
• Albuterol nebulization (10–20 mg).
• Dialysis if refractory or ECG changes.
• Metabolic acidosis (pH <7.1): Bicarbonate.
• Fluid overload: Diuretics (if responsive) or RRT.

---

Step 5: Indications for RRT (Dialysis)

Start RRT if AEIOU criteria are met:

• Acidosis (pH <7.1, refractory).
• Electrolyte disturbances (K⁺ >6.5 mEq/L, refractory).
• Intoxication (dialyzable toxins: lithium, methanol, ethylene glycol).
• Overload (fluid overload refractory to diuretics).
• Uremia (BUN >100 mg/dL, pericarditis, encephalopathy, bleeding).

Modality Choice:

• Intermittent Hemodialysis (IHD): Stable patients.
• Continuous RRT (CRRT): Hemodynamically unstable (ICU).
• Peritoneal Dialysis (PD): If vascular access is difficult.

---

Step 6: Supportive Care

• Nutrition:
• Protein: 0.8–1.0 g/kg/day.
• Calories: 25–30 kcal/kg/day.
• Fluid Balance:
• Restrict fluids if oliguric (insensible losses + urine output).
• Infection Prophylaxis:
• Adjust antibiotic doses for renal function.

---

Step 7: Monitor and Follow-Up

• Daily:
• SCr, BUN, electrolytes, urine output, weight, fluid balance.
• Renal Ultrasound: If no improvement in 24–48h (rule out obstruction).
• Nephrology Consult:
• Stage 2–3 AKI.
• Unclear etiology.
• Need for RRT.

---

Step 8: Prognosis and Prevention

• Prognosis:
• Mortality: ~10–30% (higher in ICU, sepsis, Stage 3).
• Recovery: Prerenal AKI often reversible; ATN may take weeks.
• ~20–30% progress to CKD.
• Prevention:
• Avoid nephrotoxins.
• Hydrate before contrast procedures.
• Optimize hemodynamics in high-risk patients.

---

Quick Reference Table: AKI Causes and Management

Type	Causes	Diagnostic Clues	Management
Pre-renal	Hypovolemia, hypotension, HF	FeNa <1%, urine osmolality >500	Fluids, optimize hemodynamics
ATN	Ischemia, toxins (aminoglycosides)	FeNa >2%, granular casts	Discontinue nephrotoxins, supportive
AIN	Drugs (penicillin, PPIs, NSAIDs)	Eosinophils in urine, rash, fever	Stop drug, ± steroids
Glomerulonephritis	Immune-mediated (e.g., vasculitis)	Proteinuria, hematuria, low C3/C4	Immunosuppression (steroids, cyclophosphamide)
Post-renal	Obstruction (stones, BPH, tumors)	Hydronephrosis on ultrasound	Catheterization, nephrostomy, stenting